Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C

World Journal of Gastroenterology

Volumn 16, Issue 21, 2010, Pages 2638-2647

  Gomez, Eduardo Vilar ^a   Perez, Yadina Martinez ^a   Sanchez, Hector Vega ^a   Forment, Gretel Riveron ^b   Soler, Enrique Arus ^a   Bertot, Luis Calzadilla ^a   Garcia, Ali Yasells ^a   Vazquez, Maria del Rosario Abreu ^a   Fabian, Licet Gonzalez ^a  

^a INSTITUTO DE GASTROENTEROLOGÍA   (Cuba)

^b National Center   (Cuba)

Author keywords

Antioxidant therapy; Chronic hepatitis c; Cytokines; Immunomodulatory therapy; Nutritional supplement; Oxidative stress

Indexed keywords

ANTIOXIDANT; GAMMA INTERFERON; INTERLEUKIN 10; MALONALDEHYDE; PEGINTERFERON; PLACEBO; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIUSID;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 77953504745     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i21.2638     Document Type: Article

References (48)

1. Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521-526
2. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-2451
3. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginter-feron with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850
4. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838
5. De Maria N, Colantoni A, Fagiuoli S, Liu GJ, Rogers BK, Farinati F, Van Thiel DH, Floyd RA. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med 1996; 21: 291-295
6. Boya P, de la Peña A, Beloqui O, Larrea E, Conchillo M, Castelruiz Y, Civeira MP, Prieto J. Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Hepatol 1999; 31: 808-814
7. Swietek K, Juszczyk J. Reduced glutathione concentration in erythrocytes of patients with acute and chronic viral hepatitis. J Viral Hepat 1997; 4: 139-141
8. Ko WS, Guo CH, Yeh MS, Lin LY, Hsu GS, Chen PC, Luo MC, Lin CY. Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C. World J Gastroen-terol 2005; 11: 4697-4702
9. Jain SK, Pemberton PW, Smith A, McMahon RF, Burrows PC, Aboutwerat A, Warnes TW. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol 2002; 36: 805-811
10. Gramenzi A, Andreone P, Loggi E, Foschi FG, Cursaro C, Margotti M, Biselli M, Bernardi M. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepat 2005; 12: 525-530
11. Neumann-Haefelin C, Timm J, Spangenberg HC, Wischnio-wski N, Nazarova N, Kersting N, Roggendorf M, Allen TM, Blum HE, Thimme R. Virological and immunological determinants of intrahepatic virus-specifc CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology 2008; 47: 1824-1836
12. Sarih M, Bouchrit N, Benslimane A. Different cytokine profiles of peripheral blood mononuclear cells from patients with persistent and self-limited hepatitis C virus infection. Immunol Lett 2000; 74: 117-120
13. Brooks DG, Triflo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006; 12: 1301-1309
14. Pham TN, Mercer SE, Michalak TI. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profles. J Viral Hepat 2009; 16: 547-556
15. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, Cabrera R, Liu C, Davis GL. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003; 38: 859-868
16. Farinati F, Cardin R, Bortolami M, Guido M, Rugge M. Oxi-dative damage, pro-inflammatory cytokines, TGF-alpha and c-myc in chronic HCV-related hepatitis and cirrhosis. World J Gastroenterol 2006; 12: 2065-2069
17. Zekri AR, Ashour MS, Hassan A, Alam El-Din HM, El-Shehaby AM, Abu-Shady MA. Cytokine profle in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World J Gastroenterol 2005; 11: 6624-6630
18. Groenbaek K, Friis H, Hansen M, Ring-Larsen H, Krarup HB. The effect of antioxidant supplementation on hepatitis C viral load, transaminases and oxidative status: a randomized trial among chronic hepatitis C virus-infected patients. Eur J Gastroenterol Hepatol 2006; 18: 985-989
19. Marotta F, Yoshida C, Barreto R, Naito Y, Packer L. Oxida-tive-inflammatory damage in cirrhosis: effect of vitamin E and a fermented papaya preparation. J Gastroenterol Hepatol 2007; 22: 697-703
20. Gabbay E, Zigmond E, Pappo O, Hemed N, Rowe M, Za-brecky G, Cohen R, Ilan Y. Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial. World J Gastroenterol 2007; 13: 5317-5323
21. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Di-enstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008; 47: 605-612
22. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology 2007; 132: 1925-1936
23. Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. J Hepa-tol 2007; 46: 734-742
24. Duarte TL, Lunec J. Review: When is an antioxidant not an antioxidant? A review of novel actions and reactions of vitamin C. Free Radic Res 2005; 39: 671-686
25. Kang YJ, Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Mol Aspects Med 2005; 26: 391-404
26. Lee CH, Park SW, Kim YS, Kang SS, Kim JA, Lee SH, Lee SM. Protective mechanism of glycyrrhizin on acute liver injury induced by carbon tetrachlorside in mice. Biol Pharm Bull 2007; 30: 1898-1904
27. Vilar Gomez E, Gra Oramas B, Soler E, Llanio Navarro R, Ruenes Domech C. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Liver Int 2007; 27: 247-259
28. Fulbert JC, Succari M, Cals MJ. Semi-automated assay of erythrocyte Cu-Zn superoxide dismutase activity. Clin Bio-chem 1992; 25: 115-119
29. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drüeke T, Descamps-Latscha B. Advanced oxidation protein products as novel mediators of inflammation and mono-cyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532
30. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968; 25: 192-205
31. Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L, Yasells Garcia A, Del Rosario Abreu Vazquez M. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009; 30: 999-1009
32. Yadav D, Hertan HI, Schweitzer P, Norkus EP, Pitchumoni CS. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2634-2639
33. Paradis V, Mathurin P, Kollinger M, Imbert-Bismut F, Charlotte F, Piton A, Opolon P, Holstege A, Poynard T, Bedossa P. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997; 50: 401-406
34. Zamara E, Novo E, Marra F, Gentilini A, Romanelli RG, Ca-ligiuri A, Robino G, Tamagno E, Aragno M, Danni O, Autelli R, Colombatto S, Dianzani MU, Pinzani M, Parola M. 4-Hy-droxynonenal as a selective pro-fbrogenic stimulus for activated human hepatic stellate cells. J Hepatol 2004; 40: 60-68
35. Prasad AS, Beck FW, Bao B, Fitzgerald JT, Snell DC, Steinberg JD, Cardozo LJ. Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress. Am J Clin Nutr 2007; 85: 837-844
36. Huang HY, Appel LJ, Croft KD, Miller ER 3rd, Mori TA, Puddey IB. Effects of vitamin C and vitamin E on in vivo lipid peroxidation: results of a randomized controlled trial. Am J Clin Nutr 2002; 76: 549-555
37. Friedman SL. Liver fbrosis -- from bench to bedside. J Hepa-tol 2003; 38 Suppl 1: S38-S53
38. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999; 19: 157-169
39. Neuman MG, Benhamou JP, Marcellin P, Valla D, Malk-iewicz IM, Katz GG, Trepo C, Bourliere M, Cameron RG, Cohen L, Morgan M, Schmilovitz-Weiss H, Ben-Ari Z. Cyto-kine--chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 2007; 149: 126-136
40. Trinchieri G. Regulatory role of T cells producing both in-terferon gamma and interleukin 10 in persistent infection. J Exp Med 2001; 194: F53-F57
41. Piazzolla G, Tortorella C, Schiraldi O, Antonaci S. Relationship between interferon-gamma, interleukin-10, and interleukin-12 production in chronic hepatitis C and in vitro effects of interferon-alpha. J Clin Immunol 2000; 20: 54-61
42. Eskdale J, Keijsers V, Huizinga T, Gallagher G. Microsat-ellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1999; 1: 151-155
43. Abe M, Akbar F, Hasebe A, Horiike N, Onji M. Glycyrrhizin enhances interleukin-10 production by liver dendritic cells in mice with hepatitis. J Gastroenterol 2003; 38: 962-967
44. Prasad AS. Zinc in human health: effect of zinc on immune cells. Mol Med 2008; 14: 353-357
45. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001; 38: 263-355
46. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, Wang TJ, Benjamin EJ, D'Agostino RB, Vasan RS. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007; 27: 127-133
47. Ruhl CE, Everhart JE. Elevated serum alanine aminotrans-ferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009; 136: 477-485. e11
48. Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma gluta-myltransferase a marker of oxidative stress? Free Radic Res 2004; 38: 535-539